Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067 and the Combination of GLPG3067 and GLPG2222 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067

Trial Profile

Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067 and the Combination of GLPG3067 and GLPG2222 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs GLPG 2222 (Primary) ; GLPG 3067 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
    • 20 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
    • 22 Aug 2017 Planned number of patients changed from 65 to 81.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top